OBJECTIVE: We retrospectively analysed our experience with the subclavian access transcatheter aortic valve implantation (TAVI) with the self-expandable CoreValve prosthesis and compared the results with transfemorally treated patients. BACKGROUND: For TAVI, a subclavian access is alternatively used when the femoral arteries are diseased or very small. METHODS: Between June 2007 and February 2011, 341 patients underwent CoreValve implantation in the German Heart Center, Munich through either transfemoral (n = 301) or subclavian (n = 40) approach. The subclavian approach was chosen where transfemoral approach was not possible. RESULTS: There was no difference in baseline characteristics between the groups. There were no significant differences between groups for parameters potentially related to improved valve positioning (contrast medium, fluoroscopy time, implantation of a second valve, post-implantation balloon dilatation, valve dislocation, pacemaker implantation, aortic regurgitation), while the procedure duration was longer (105 ± 40 vs. 82 ± 33 min, p = 0.001). With the Kaplan-Meier estimate, survival was not different among groups. Strokes, myocardial ischaemia, and access vessel complications occurred in 2.5, 0, and 7.5 % (subclavian group) vs. 4.3, 2.0, 10.6 % (transfemoral group), ns. CONCLUSIONS: Our results demonstrate the safety of the subclavian access for TAVI and comparability with the transfemoral approach. With longer duration of the procedure and no significant advantages in clinical outcome, the subclavian access will have an indication for selected patients, while transfemoral TAVI should be considered first choice.
OBJECTIVE: We retrospectively analysed our experience with the subclavian access transcatheter aortic valve implantation (TAVI) with the self-expandable CoreValve prosthesis and compared the results with transfemorally treated patients. BACKGROUND: For TAVI, a subclavian access is alternatively used when the femoral arteries are diseased or very small. METHODS: Between June 2007 and February 2011, 341 patients underwent CoreValve implantation in the German Heart Center, Munich through either transfemoral (n = 301) or subclavian (n = 40) approach. The subclavian approach was chosen where transfemoral approach was not possible. RESULTS: There was no difference in baseline characteristics between the groups. There were no significant differences between groups for parameters potentially related to improved valve positioning (contrast medium, fluoroscopy time, implantation of a second valve, post-implantation balloon dilatation, valve dislocation, pacemaker implantation, aortic regurgitation), while the procedure duration was longer (105 ± 40 vs. 82 ± 33 min, p = 0.001). With the Kaplan-Meier estimate, survival was not different among groups. Strokes, myocardial ischaemia, and access vessel complications occurred in 2.5, 0, and 7.5 % (subclavian group) vs. 4.3, 2.0, 10.6 % (transfemoral group), ns. CONCLUSIONS: Our results demonstrate the safety of the subclavian access for TAVI and comparability with the transfemoral approach. With longer duration of the procedure and no significant advantages in clinical outcome, the subclavian access will have an indication for selected patients, while transfemoral TAVI should be considered first choice.
Authors: Arnaud Van Linden; Johannes Blumenstein; Thomas Walther; Helge Möllmann; Won Keun Kim; Christian Hamm; Jörg Kempfert Journal: Clin Res Cardiol Date: 2012-11-06 Impact factor: 5.460
Authors: Anna Sonia Petronio; Marco De Carlo; Francesco Bedogni; Antonio Marzocchi; Silvio Klugmann; Francesco Maisano; Angelo Ramondo; Gian Paolo Ussia; Federica Ettori; Arnaldo Poli; Nedy Brambilla; Francesco Saia; Federico De Marco; Antonio Colombo Journal: Circ Cardiovasc Interv Date: 2010-07-06 Impact factor: 6.546
Authors: Lenard Conradi; Moritz Seiffert; Olaf Franzen; Stephan Baldus; Johannes Schirmer; Thomas Meinertz; Hermann Reichenspurner; Hendrik Treede Journal: Clin Res Cardiol Date: 2010-10-21 Impact factor: 5.460
Authors: Sabine Bleiziffer; Hendrik Ruge; Domenico Mazzitelli; Andrea Hutter; Anke Opitz; Robert Bauernschmitt; Rüdiger Lange Journal: J Thorac Cardiovasc Surg Date: 2009-09-17 Impact factor: 5.209
Authors: Nicolas A Geis; Emmanuel Chorianopoulos; Klaus Kallenbach; Florian André; Sven T Pleger; Matthias Karck; Hugo A Katus; Raffi Bekeredjian Journal: Clin Res Cardiol Date: 2014-04-21 Impact factor: 5.460
Authors: Thom G Dahle; Nathaniel J Castro; Brian M Stegman; Jacob R Dutcher; John M Teskey; Wade T Schmidt; Daren S Danielson; Sara J Dezell; Virginia B Daniels; Daniel J Tiede Journal: J Cardiothorac Surg Date: 2018-01-30 Impact factor: 1.637